Photo from wikipedia
The rollout of dolutegravir (DTG) in low‐ and middle‐income countries was disrupted by a potential association reported with periconceptional DTG exposure among women living with HIV (WLHIV) and infant neural… Click to show full abstract
The rollout of dolutegravir (DTG) in low‐ and middle‐income countries was disrupted by a potential association reported with periconceptional DTG exposure among women living with HIV (WLHIV) and infant neural tube defects. This prompted countries to issue interim guidance limiting DTG use among women of reproductive potential to those on effective contraception. Data to understand the potential impact of such guidance on WLHIV are limited.
Keywords:
dolutegravir;
among women;
use hiv;
contraception use;
hiv outcomes
Journal Title: Journal of the International AIDS Society
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the International AIDS Society
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!